Is Helix BioMedix Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Helix BioMedix Inc (HXBM) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Helix BioMedix Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Helix BioMedix Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Helix BioMedix Inc?

Muslim investors may consider investing in Helix BioMedix Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Helix BioMedix Inc classified as NOT COVERED?

Musaffa determines the Shariah status of Helix BioMedix Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Helix BioMedix Inc updated?

The Shariah compliance status of Helix BioMedix Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Helix BioMedix Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Helix BioMedix Inc?

You can check the latest Shariah compliance status of Helix BioMedix Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Helix BioMedix Inc. Stock Analysis HXBM

United States Health Care Nano Cap

Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum. The company is headquartered in Bothell, Washington and currently employs 8 full-time employees. The company went IPO on 2000-07-25. The firm is in the preclinical stage of development and intends to file for orphan drug designation prior to entering the clinical development pathway. Its legacy business consists of an proprietary library of patented bioactive peptides. Its lead drug development candidate, HB4208, is a polypeptide DNA deoxyribonucleic (DNA) damage response (DDR) enzyme for topical treatment of the rare genetic disorder (orphan disease) XP. Its intellectual property portfolio offers multiple pathways for commercialization in this area ranging from Rx dermatology to aesthetic dermatology and personal care. The company is developing new treatment options for dermatologic conditions which offer the therapeutic effectiveness and safety benefits of its advanced bioactive small molecule technology. The company is also engaged in the treatment of skin conditions.

Key Statistics of Helix BioMedix Inc (HXBM)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$1.79$1.79

Today's Open

$1.79

Volume

150.00

P/E Ratio (TTM)

52 Week Range

$1.00$6.45

Market Cap

402.23K

Avg. Volume

709.67

Dividend Yield

Financial Metrics & Statements of Helix BioMedix Inc (HXBM)

FAQ's for Helix BioMedix Inc (HXBM)

According to Musaffa’s Shariah screening methodology, Helix BioMedix Inc (HXBM) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.